Photosensitizing antibody-fluorophore conjugates
The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm −2 , thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
1. A method of treating a tumor in a subject, comprising:
administering to the subject a therapeutically effective amount of one or more antibody-IR700 molecules, wherein the antibody specifically binds to a cell surface protein on the tumor; and
irradiating the tumor at a wavelength of 660 to 740 nm and at a dose of at least 1 J cm −2 , thereby treating the tumor in the subject.
2. The method of claim 1 , wherein the tumor is a cancer.
3. The method of claim 2 , wherein the cancer is a cancer of the breast, liver, colon, ovary, prostate, pancreas, brain, cervix, bone, skin, or lung.
4. The method of claim 2 , wherein the cancer is a cancer of the blood.
5. The method of claim 1 , wherein the cell surface protein is a tumor-specific protein.
6. The method of claim 5 , wherein the tumor-specific protein is HER1, HER2, CD20, CD25, CD33, CD52, or prostate specific membrane antigen (PSMA).
7. The method of claim 6 , wherein the one or more antibody-IR700 molecules comprise a Panitumumab-IR700 molecule, Trastuzumab-IR700 molecule, or J591-IR700 molecule.
8. The method of claim 1 , wherein the tumor is irradiated at a wavelength of 680 nm.
9. The method of claim 1 , wherein the tumor is in a subject's blood, and wherein irradiating the tumor comprises irradiating the blood by using a device worn by the subject, wherein the device comprises a near infrared (NIR) light emitting diode (LED).
10. The method of claim 1 , wherein the method further comprises:
selecting a subject with a tumor that expresses a cell surface protein that can specifically bind to the antibody-IR700 molecule.
11. The method of claim 1 , wherein the method increases survival time of the subject by at least 50% relative to an absence of administration of the antibody-IR700 molecule and irradiation.
12. The method of claim 1 , further comprising:
contacting the tumor with one or more antibody-IR700 molecules in an amount less than the therapeutically effective amount; and
irradiating the tumor at a wavelength of 660 to 740 nm and at a dose of at least 0.001 J cm −2 , thereby permitting detection of the tumor.
13. The method of claim 2 , wherein the cancer is a cancer of the head and neck.
14. The method of claim 5 , wherein the tumor-specific protein is HER1, and the one or more antibody-IR700 molecules comprise a Cetuximab-IR700 molecule.
15. The method of claim 1 , wherein the administering is intravenous.
16. The method of claim 1 , wherein the tumor is a human epidermal growth factor receptor 1 (HER1)+ tumor, the cell surface protein on the tumor is HER1, and the one or more antibody-IR700 molecules comprise a Cetuximab-IR700 molecule.
17. The method of claim 16 , wherein the HER1+ tumor is an adenocarcinoma.
18. The method of claim 17 , wherein the adenocarcinoma is an adenocarcinoma of the colon, head or neck.
19. The method of claim 1 , wherein the tumor is a HER1+ tumor, the cell surface protein on the tumor is HER1, and the one or more antibody-IR700 molecules comprise a Panitumumab-IR700 molecule.
20. The method of claim 19 , wherein the HER1+ tumor is an adenocarcinoma.
21. The method of claim 20 , wherein the adenocarcinoma is an adenocarcinoma of the colon, head or neck.
22. The method of claim 1 , wherein the tumor is a HER2+ tumor, the cell surface protein on the tumor is HER2, and the one or more antibody-IR700 molecules comprise a Trastuzumab-IR700 molecule.
23. The method of claim 22 , wherein the HER2+ tumor is a cancer of the breast, ovary, stomach, or uterus.
24. The method of claim 1 , wherein the tumor is a prostate-specific membrane antigen (PSMA)+ tumor, the cell surface protein on the tumor is PMSA, and the one or more antibody-IR700 molecules comprise a J591-IR700 molecule.
25. The method of claim 1 , wherein the tumor is a metastasis.